Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Accured Expenses (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Change in Accured Expenses for 16 consecutive years, with $141000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 115.08% to $141000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.5 million, a 59.12% increase, with the full-year FY2025 number at -$1.5 million, up 59.12% from a year prior.
  • Change in Accured Expenses was $141000.0 for Q4 2025 at Anika Therapeutics, down from $3.6 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.6 million in Q3 2023 to a low of -$4.3 million in Q2 2023.
  • A 5-year average of -$22700.0 and a median of $273500.0 in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 287.22% in 2021, then crashed 567.67% in 2024.
  • Anika Therapeutics' Change in Accured Expenses stood at $406000.0 in 2021, then crashed by 237.44% to -$558000.0 in 2022, then skyrocketed by 231.54% to $734000.0 in 2023, then plummeted by 227.38% to -$935000.0 in 2024, then surged by 115.08% to $141000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Change in Accured Expenses are $141000.0 (Q4 2025), $3.6 million (Q3 2025), and -$2.2 million (Q2 2025).